Revenue and Profitability - The company's revenue for Q1 2025 was ¥148,463,072.45, representing a 15.68% increase compared to ¥128,337,109.62 in the same period last year[5]. - The net profit attributable to shareholders was -¥134,684,765.54, an improvement of 30.40% from -¥193,523,888.81 year-on-year[5]. - The total profit increased by 32.19% year-on-year, attributed to reduced expenses[8]. - The company reported a net loss of approximately ¥134.99 million, compared to a net loss of ¥194.15 million in the previous period, representing a 30.4% improvement in net loss year-over-year[18]. - Operating profit was recorded at approximately -¥167.73 million, an improvement from -¥246.24 million in the prior period, indicating a 32% reduction in operating losses[18]. Cash Flow and Financial Activities - The net cash flow from operating activities improved by 64.02%, reaching -¥185,768,066.30 compared to -¥516,257,943.00 in the previous year[5][11]. - The company reported a 50.23% increase in net cash flow from financing activities, mainly due to reduced lease payments[11]. - Cash flow from operating activities showed a net outflow of approximately -¥185.77 million, an improvement from -¥516.26 million in the previous year, reflecting a 64% reduction in cash outflow[20]. - The company’s investment activities resulted in a net cash outflow of approximately -¥19.16 million, compared to -¥27.51 million in the previous period, indicating a 30.3% improvement[21]. - The company’s financing activities resulted in a net cash outflow of approximately -¥2.81 million, compared to -¥5.65 million in the previous period, reflecting a 50.3% reduction in cash outflow[21]. Assets and Liabilities - Total assets decreased by 4.81% to ¥6,851,934,090.73 from ¥7,198,413,777.39 at the end of the previous year[5]. - Total liabilities decreased to ¥1,338,069,738.19 from ¥1,549,142,585.25, indicating a decline of about 13.6%[15]. - The company's total equity decreased to ¥5,513,864,352.54 from ¥5,649,271,192.14, reflecting a decrease of approximately 2.4%[15]. - Accounts receivable decreased to ¥1,367,828,160.04 from ¥1,541,076,525.80, a decline of about 11.3%[13]. - Cash and cash equivalents at the end of the period amounted to ¥1,739,155,105.06, down from ¥1,948,949,584.50, a decline of about 10.7%[13]. Operating Performance - Operating income increased by 305.36% compared to the previous year, mainly due to received penalties[7]. - Total operating revenue for the current period reached ¥148,463,072.45, an increase from ¥128,337,109.62 in the previous period, reflecting a growth of approximately 15.6%[17]. - Total operating costs decreased to ¥331,070,626.05 from ¥388,390,012.30, indicating a reduction of about 14.7%[17]. - Research and development expenses were ¥106,637,544.37, down from ¥151,690,226.17, showing a decrease of approximately 29.7%[17]. - The company incurred cash outflows for purchasing goods and services totaling approximately ¥337.67 million, down from ¥430.08 million, a decrease of 21.5%[20]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 77,425[10].

Financial Performance - The company's operating revenue for 2024 was ¥440,478,600.49, representing a 400.31% increase compared to ¥88,040,600.80 in 2023[20]. - The net profit attributable to shareholders for 2024 was -¥113,006,166.29, a slight improvement of 5.92% from -¥120,115,833.29 in 2023[20]. - The net cash flow from operating activities for 2024 was -¥479,582,657.09, a significant decline of 818.32% compared to -¥52,224,007.16 in 2023[20]. - Total assets at the end of 2024 reached ¥1,470,823,932.83, an increase of 23.33% from ¥1,192,593,505.11 at the end of 2023[20]. - The company's net assets attributable to shareholders decreased by 20.44% to ¥820,299,187.95 at the end of 2024 from ¥1,031,077,872.65 at the end of 2023[20]. - Non-recurring gains for 2024 amounted to ¥18,295,621.80, compared to ¥12,380,814.32 in 2023, primarily from asset disposals and government subsidies[25][26]. - The company's basic earnings per share for 2024 was -¥0.1045, a slight improvement of 1.32% from -¥0.1059 in 2023[20]. - The total amount of accounts receivable confirmed during the reporting period was ¥6,737.57 million[52]. - The company's total operating costs reached ¥405,224,302.75, a significant increase of 688.43% compared to the previous year[55]. - The total distributable profit for the reporting period was -419,349,894.07 CNY, indicating a loss[130]. Business Operations - The main business operations include veterinary vaccines, copper-clad laminates, and animal nutrition (feed) as of the report date[18]. - The company has strategically exited the fine enameled wire business as of the end of Q3 2022, focusing on its new business segments[18]. - The animal nutrition business has seen monthly sales growth due to increased market demand, despite being in its early development stage with only 2 months of operational experience[34]. - The company has established a comprehensive procurement management system to reduce costs while ensuring stable quality, adapting to market changes[33]. - The company is focusing on enhancing product quality, optimizing sales channels, and improving production capacity to better its profitability[36]. - The company has implemented a strategic transformation to improve operational conditions and expand its business scope, aiming to eliminate delisting risk warnings[43]. - The company has upgraded its production facilities to meet the latest GMP standards, ensuring the safety, effectiveness, and quality stability of its vaccines[39]. - The company aims to position itself as a "vaccine process expert and disease solution expert," focusing on high-quality vaccine production and comprehensive technical services for livestock farms[40]. Market Conditions - The company reported a significant decline in the pig farming industry, with a 3.31% decrease in the national pig slaughter volume to 703 million heads in 2024[28]. - The average price of pigs showed signs of recovery starting in Q2 2024, but this did not translate to improved conditions for upstream animal health companies[28]. - The company faced intense competition in the animal health sector, with price wars becoming the norm due to prolonged payment cycles and low bidding standards[28]. - The pig vaccine business has faced increased competition, leading to a decline in product gross margins and longer accounts receivable periods[33]. - The feed industry is evolving towards green and intelligent production in response to environmental policies and customized demands[29]. Research and Development - The company has established a comprehensive innovation system through collaborations with top research institutions, resulting in 9 new veterinary drug registration certificates and 33 invention patents[37]. - A new live vaccine for pseudorabies (JS-A1 strain) developed in collaboration with the Chinese Academy of Agricultural Sciences received a new veterinary drug certificate in November 2024, marking it as the first of its kind in China[38]. - The company has a total of 31 vaccine products registered, including 15 for pigs and 16 for poultry, and continues to enhance its product offerings to strengthen market competitiveness[39]. - R&D investment increased by 28.89% to ¥15,564,041.87 in 2024, while the proportion of R&D investment to operating revenue decreased to 3.53% from 13.72%[63]. - The number of R&D personnel rose by 29.55% to 57 in 2024, with a significant increase in master's degree holders by 41.18%[63]. Governance and Management - The company has established a governance structure that complies with relevant laws and regulations, ensuring independent operations and decision-making processes[97]. - The board of directors consists of 7 members, including 3 independent directors, meeting regulatory requirements for governance[98]. - The company has implemented a strategic plan to enhance market competitiveness and is committed to ongoing innovation in response to industry trends and customer needs[90]. - The company has established a comprehensive investor relations management system to enhance communication and ensure investors' rights are protected[99]. - The company has implemented a public opinion response management system to effectively handle various public sentiments impacting stock prices and business reputation[99]. Environmental Compliance - The company has complied with all relevant environmental protection laws and regulations during its operations[141]. - The total investment in environmental protection measures for 2024 by Shiji Biological amounted to CNY 268,360, including wastewater treatment agents, environmental taxes, hazardous waste disposal, and equipment maintenance[150]. - The companies are actively complying with local environmental regulations and have established measures to manage and monitor their emissions[145]. - Shiji Biological successfully executed its environmental self-monitoring plan during the reporting period without any exceedances[147]. Shareholder Relations - The company reported a profit distribution plan of 0 cash dividends and 0 bonus shares per 10 shares for all shareholders[5]. - The company did not propose any cash dividend distribution plan for the reporting period despite having a positive profit available for distribution to shareholders[132]. - The company plans to maintain its share repurchase strategy in 2024 but will not distribute cash dividends or issue bonus shares[132]. - The participation rate for the 2024 first extraordinary shareholders' meeting was 40.17%[102]. - The company completed the repurchase of 101,720,721 shares, accounting for 8.96% of the total share capital, which is treated as a cash dividend[128]. Risks and Challenges - The company has faced a decline in its veterinary vaccine business for two consecutive years, with sales at a low level, indicating high market competition risks[89]. - The company is addressing raw material price volatility risks, which could significantly impact costs and profits, by closely monitoring market trends and exploring strategic supplier relationships[92]. - The company has a high customer concentration in its feed business, which poses risks if customer relationships deteriorate; it plans to actively develop new markets to mitigate this risk[91]. - The company emphasizes the importance of managing accounts receivable to prevent bad debt risks as its business scales up, despite currently having a low bad debt rate[93]. Audit and Compliance - The company received a standard unqualified audit report for the 2024 fiscal year, with audited revenue exceeding 300 million yuan[188]. - The 2023 audit report highlighted concerns regarding the controlling shareholder's bankruptcy proceedings, which have since been addressed, ensuring no significant impact on the company's operations[187]. - The company identified and corrected significant internal control deficiencies related to revenue recognition and inflated income from subsidiary Chengdu Shiji Bio-Pharmaceutical Co., Ltd., with corrections made prior to the annual report[189][190]. - The company has implemented measures to strengthen internal controls, including revising organizational structures and enhancing management oversight to prevent future issues[191].

Financial Performance - The company's operating revenue for 2024 was ¥2,467,273,131.54, a decrease of 19.71% compared to ¥3,072,775,783.47 in 2023[19]. - The net profit attributable to shareholders for 2024 was ¥158,150,563.89, down 54.65% from ¥348,762,592.11 in 2023[19]. - The net profit after deducting non-recurring gains and losses was ¥101,796,633.14, a decline of 66.23% from ¥301,463,171.95 in 2023[19]. - The basic earnings per share for 2024 was ¥0.1870, a decrease of 54.64% compared to ¥0.4123 in 2023[19]. - The total assets at the end of 2024 were ¥7,198,413,777.39, a decrease of 5.62% from ¥7,626,804,388.40 at the end of 2023[19]. - The cash flow from operating activities was negative at -¥470,030,677.59, a decline of 178.69% from ¥597,317,693.97 in 2023[19]. - The weighted average return on equity for 2024 was 2.83%, down 3.65 percentage points from 6.48% in 2023[19]. - The total revenue for 2024 was ¥2,467,273,131.54, representing a decrease of 19.71% compared to ¥3,072,775,783.47 in 2023[67]. - Revenue from the password segment was ¥1,422,604,393.20, accounting for 57.66% of total revenue, with a year-over-year decline of 3.53%[67]. - Revenue from the network security segment was ¥932,182,001.42, which saw a significant drop of 36.58% from the previous year[67]. - The gross margin for the data security and network security industry was 40.77%, down by 1.56% compared to the previous year[70]. Research and Development - The company has increased its R&D investment in core areas such as cryptography, cybersecurity, and data security, focusing on commercial cryptography and security services[33]. - The company has developed a comprehensive data security product system focusing on data governance, protection, compliance, and circulation, leveraging traditional and advanced cryptography technologies[42]. - The company has independently developed over 70 product models that have passed various national certifications, including those from the National Cryptography Administration and the Ministry of Public Security[52]. - In the reporting period, the company applied for more than 130 invention patents, with nearly 30 patents granted, focusing on new technology fields such as artificial intelligence and 5G[52]. - Research and development expenses decreased by 9.26% year-over-year, amounting to ¥383,725,530.05[78]. - Research and development (R&D) expenditure amounted to 438,198,557.54 yuan, representing 17.76% of operating revenue, an increase of 2.08% from the previous year[82]. - The number of R&D personnel decreased slightly to 1,095, a reduction of 0.18%, while the proportion of R&D staff increased to 36.94%[82]. Market and Business Development - The company is actively developing new business areas such as vehicle networking and satellite internet, which are seen as new growth points[33]. - The company is focusing on developing data encryption products and compliance auditing systems to meet government and central enterprise needs[64]. - The company is actively expanding its market presence in the fields of password, network security, and data security, aiming to establish itself as a leading data intelligent security service provider[63]. - The company is positioned to benefit from the "Strong Password Nation" initiative, with increasing market demand for cybersecurity solutions driven by regulatory changes and digital economy growth[56]. - The company aims to enhance its profitability by increasing the proportion of self-developed products and optimizing its business structure through strong core businesses in cryptography, network security, and data security[48]. Governance and Compliance - The company has acknowledged uncertainties regarding its ability to continue as a going concern, as indicated in the audit report[19]. - The company has established a market value management system to protect investor rights and enhance investment value, approved by the board on April 25, 2025[118]. - The company strictly adheres to relevant laws and regulations, ensuring compliance with corporate governance standards set by the China Securities Regulatory Commission[120]. - The internal audit department operates independently, reporting directly to the audit committee, and conducts regular audits of financial and operational activities[128]. - The company has established specialized committees within the board to enhance governance and promote sustainable development[123]. - The company has implemented a structured approach to assess and determine the remuneration of its senior management[144]. - The company has committed to maintaining transparency with investors regarding the progress and expected outcomes of its investment projects[100]. Social Responsibility and Environmental Impact - The company actively participated in social responsibility initiatives, including educational donations and support for special groups, contributing to community development[185]. - In 2024, the company purchased 563,000 yuan worth of agricultural products from poverty-stricken areas, supporting local industry development[186]. - The company has implemented a green low-carbon development strategy, promoting energy-saving measures and resource recycling[184]. - The company achieved a 99% purification rate for welding exhaust emissions using the METCAL dust purification system, ensuring no impact on workers and local communities[183]. - The company received a "BBB" rating in its first ESG report and was recognized as a new rising star in ESG responsibility[185]. Leadership and Management Changes - The company experienced a change in senior management with multiple resignations effective in 2024[134]. - The company has a new board chairman, Chen Xin, who has been in position since May 2024[135]. - The company appointed independent directors Huang Weiping and Tang Guangxing in May 2024, bringing extensive financial and management experience[138][139]. - The company is expanding its leadership team with new appointments, including General Manager Wei Min and Deputy General Manager Wang Yunbing in July 2024[142]. - The company is committed to maintaining strong governance with the appointment of experienced independent directors[137]. Financial Commitments and Performance Guarantees - The actual controller and shareholders of the company have fulfilled their performance commitments for the reporting period, including a net profit commitment of no less than 9.2029 million yuan for 2022, 9.5140 million yuan for 2023, and 9.4179 million yuan for 2024[188]. - The company guarantees to avoid any direct or indirect competition with its subsidiary, ensuring independence in operations, assets, finance, and business activities[189]. - The performance compensation obligations will be strictly adhered to by the responsible parties involved in the transaction[188]. - The company has outlined its obligations to facilitate compliance with related party transaction regulations for its controlled subsidiaries[189].

贤丰控股股份有限公司 2025 年第一季度报告 证券代码：002141 证券简称：*ST 贤丰 公告编号：2025-035 贤丰控股股份有限公司 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 | | | 单位：元 | | --- | --- | --- | | 项目 | 本报告期金额 | 说明 | | 非流动性资产处置损益（包括已计提资产减值准备的冲销部分） | 18,488,785.48 | 主要系出售珠海厂房土地部分 完成过户及成都史纪技术合同 | | | | 转让所致 | 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告 ...

Financial Performance - The company's revenue for 2024 was CNY 1,182,362,768.46, representing a decrease of 8.48% compared to CNY 1,291,887,142.06 in 2023[18]. - Net profit attributable to shareholders for 2024 was CNY 39,883,176.39, down 40.38% from CNY 66,898,617.98 in 2023[18]. - Basic earnings per share decreased by 40.00% to CNY 0.12 in 2024, down from CNY 0.20 in 2023[18]. - Total assets at the end of 2024 were CNY 2,193,636,977.65, a decrease of 1.53% from CNY 2,227,773,648.98 at the end of 2023[18]. - The company reported a weighted average return on equity of 3.22% for 2024, down from 5.23% in 2023[18]. - The company achieved total operating revenue of 1,182,362,768.46 CNY in 2024, a decrease of 8.48% year-on-year[69]. - The net profit attributable to shareholders was 3,988.32 CNY, down 40.38% compared to the previous year[69]. - The revenue from chemical drug formulation manufacturing was 683,286,133.88 CNY, accounting for 57.79% of total revenue, with a year-on-year decline of 12.92%[72]. - The revenue from raw material drug manufacturing was 493,544,661.78 CNY, representing 41.74% of total revenue, with a slight decrease of 0.72%[72]. - The company's total liabilities included a significant amount of restricted assets, totaling ¥261,870,353.19 at year-end[91]. Dividend Distribution - The company plans to distribute a cash dividend of 1.5 RMB per 10 shares to all shareholders, based on a total of 334,893,286 shares[4]. - A cash dividend of 1.5 CNY per 10 shares (before tax) is proposed, amounting to a total cash dividend of 50,233,992.90 CNY, which represents 100% of the profit distribution[157]. - The company has no plans for stock dividends or capital reserve transfers to increase share capital, with all remaining undistributed profits carried forward to the next fiscal year[157]. - The total distributable profit for the fiscal year 2024 is based on the lower of the consolidated and parent company reports, which is 493,128,906.74 CNY[156]. Operational Highlights - The net cash flow from operating activities increased by 22.30% to CNY 211,187,476.03 in 2024, compared to CNY 172,679,270.44 in 2023[18]. - The company has not reported any changes in its main business since its listing[17]. - The company has established a comprehensive quality management system throughout the drug lifecycle, enhancing product competitiveness and reputation in the market[35]. - The company has established a comprehensive product matrix covering various therapeutic areas, with innovative micro-pellet formulations showing unique advantages in chronic disease treatment[46]. - The company has established a complete production and operational asset system, ensuring no asset encroachment by controlling shareholders[114]. Research and Development - The company is focusing on developing 13 cardiovascular drugs and various other therapeutic categories in 2025[83]. - The company has achieved significant progress in R&D, with multiple products like 瑞加诺生 and 美阿沙坦钾 receiving domestic and international registration approvals, expanding the product line[81]. - The company’s R&D investment amounted to 131.27 million yuan, supporting the advancement of several innovative projects, with a focus on clinical value and innovation[59]. - A total of 58 patent applications were submitted during the reporting period, with 33 patents granted, including 7 invention patents[60]. - The company has built a technical platform for high-tech drug development, enhancing its capabilities in CMO and CDMO services[62]. Market Expansion - The company is actively expanding its market presence in emerging markets such as the Middle East, South Asia, Southeast Asia, and South America, while maintaining long-term strategic partnerships with major domestic and international manufacturers[38]. - The company is actively pursuing international business in formulations, leveraging its global production platform[102]. - The company has been recognized as one of the top 100 Chinese chemical pharmaceutical companies in 2023 and has been included in the 2024 Guangdong Province Green Manufacturing List[28]. Environmental Compliance - The company strictly adheres to environmental protection policies, ensuring wastewater and air emissions meet regulatory standards[167]. - The company has installed online monitoring equipment at major discharge points to ensure real-time compliance with environmental regulations[169]. - The company achieved compliance with the stricter standards for wastewater discharge as per the Guangdong provincial regulations[168]. - The company’s hazardous waste management complies with national regulations, ensuring safe handling and disposal[171]. - The company has established an environmental management system since 2014 and received ISO 14001 certification in 2017, ensuring continuous improvement in environmental practices[199]. Governance and Management - The company has established a governance framework that ensures compliance with relevant laws and regulations, enhancing decision-making and internal control effectiveness[111]. - The company has a robust governance structure that complies with legal and regulatory requirements[112]. - The management team includes professionals with diverse backgrounds, enhancing the company's strategic capabilities in the pharmaceutical sector[126]. - The company has engaged in multiple investor communications to discuss business development, including meetings and online interactions throughout 2024[104][106][108]. - The company has implemented a "Quality and Return Dual Improvement" action plan to enhance operational quality and shareholder returns[109].

Financial Performance - The company's operating revenue for 2024 reached ¥2,969,629,754.90, representing a 180.46% increase compared to ¥1,058,848,156.80 in 2023[18]. - The net profit attributable to shareholders for 2024 was -¥2,238,085,227.54, a decrease of 32.18% from -¥1,693,221,743.58 in 2023[18]. - The cash flow from operating activities for 2024 was -¥970,790,002.46, a decline of 161.51% compared to ¥1,578,263,193.40 in 2023[18]. - The basic earnings per share for 2024 was -¥1.2905, down 32.17% from -¥0.9764 in 2023[18]. - Total assets at the end of 2024 amounted to ¥21,058,044,676.67, a decrease of 25.56% from ¥28,288,719,445.16 at the end of 2023[18]. - The company's net assets attributable to shareholders were -¥1,753,148,880.36 at the end of 2024, a significant decline of 461.52% from ¥484,936,347.18 at the end of 2023[18]. - The company reported a total revenue of ¥2,960,551,659.28 after deducting certain amounts, compared to ¥1,049,347,897.40 in 2023[18]. - The company reported a gross margin of -16.67% in the real estate sector, with operating costs rising by 111.06% year-on-year[45]. - Property sales accounted for ¥2,411,404,984.17, which is 81.20% of total revenue, showing a significant increase of 387.29% from ¥494,864,224.03 in the previous year[43]. Operational Highlights - The company operated 19 commercial projects with a total area of 1.16 million square meters, signing over 300 contracts with quality brands in 2024[31]. - The company’s commercial real estate ranking improved to 38th in the "Top 100 Commercial Real Estate" list, winning 19 industry awards including "ESG Rising Star" and "Outstanding Operator Award" in 2024[31]. - In the urban operation segment, the company managed 12 projects covering 250,000 square meters, enhancing its market presence through partnerships with local state-owned platforms[31]. - The company is focusing on commercial operation services and urban comprehensive operation, expanding its business footprint across major cities in China[30]. - The company is leveraging its shareholder's strengths to transition from a regional to a national player in the commercial real estate market[30]. - The company opened new long-term rental apartment projects in Shanghai and Wuhan[32]. - The total pre-sold area for major projects reached 1,000,000 square meters, with a sales amount of 1.2 billion yuan, reflecting a 20% increase year-on-year[33]. - The average rental rate for major projects is 85%, with the highest rental rate recorded at 100% for several properties[34]. Strategic Initiatives - The company aims to enrich its service offerings and improve customer engagement through innovative service spaces[32]. - The company plans to expand its market presence in Wuhan and Chengdu, targeting a 15% growth in rental income for the next fiscal year[34]. - New product launches are expected to contribute an additional 300 million yuan in revenue over the next two quarters[33]. - The company aims to increase its market share in the residential sector by 10% through strategic acquisitions and partnerships[33]. - The company is committed to optimizing its equity structure and enhancing project acquisition capabilities through its major shareholder, Electric Power Construction Real Estate[40]. Governance and Management - The board of directors consists of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[80]. - The company maintains independence from its controlling shareholder in terms of personnel, assets, finance, organization, and business operations[83]. - The company has implemented an internal audit system to enhance operational compliance and protect shareholder rights[82]. - The company emphasizes investor relations management through various communication channels to address investor inquiries and feedback[82]. - The company has established a clear organizational structure that operates independently and efficiently according to its articles of association[84]. - The company has established a performance management system that evaluates employees based on work attitude, business ability, management capability, and growth[81]. Risks and Challenges - The company faces market risks due to the regional nature of the real estate market, necessitating careful monitoring and adjustment of investment strategies[73]. - The company also faces operational risks related to the long development cycles and regulatory approvals required in real estate development[74]. - The real estate industry is capital-intensive, requiring significant funding and long-term financing plans to ensure cash flow security[75]. - There are significant uncertainties regarding the company's ability to continue as a going concern[199]. Financial Position and Liabilities - The company has a total financing balance of ¥340,630.04 million, with bank loans constituting ¥242,520.25 million at an average financing cost of 3.31%[35]. - The company reported a negative net asset value attributable to the parent company as of the end of the 2024 fiscal year, which may lead to a delisting risk warning effective April 30, 2025[151]. - The cash balance is reported at 588 million yuan, while current liabilities amount to 17.44 billion yuan[198]. - Long-term borrowings and accrued interest due within one year total 1.15 billion yuan[198]. Shareholder Information - The largest shareholder, China Electric Power Construction Group, holds 22.43% of the shares, totaling 388,986,300 shares[183]. - Wuhan New World Investment Co., Ltd. is the second largest shareholder with an 18.06% stake, amounting to 313,215,900 shares[183]. - The total number of shareholders at the end of the reporting period was 57,314[182]. - The actual controller, China Power Construction Group, Co., Ltd., holds 53.05% of the shares in the company as of the end of the reporting period[187]. Audit and Compliance - The audit report indicates a "clean opinion" with a significant uncertainty regarding the company's ability to continue as a going concern[196]. - The audit was conducted by Lixin Accounting Firm, with the report dated April 28, 2025[196]. - The company has established a robust internal control system that is effective and covers major aspects of its operations, with no significant omissions identified[117].

Financial Performance - The company's revenue for Q1 2025 was ¥254,703,072.24, a decrease of 16.79% compared to ¥306,093,972.60 in the same period last year[5] - Net profit attributable to shareholders was ¥1,868,170.85, down 93.57% from ¥29,055,820.54 year-on-year[5] - The basic and diluted earnings per share dropped by 88.89% to ¥0.01 from ¥0.09 in the same period last year[5] - The company experienced a 90.46% decline in total profit, which amounted to ¥3,200,157.00 compared to ¥33,527,966.43 in the previous year, primarily due to policy impacts on formulation products[8] - Total comprehensive income attributable to the parent company was CNY 1,868,113.62, a decrease from CNY 29,056,328.01 in the previous period[18] - Net profit fell to ¥1.87 million compared to ¥29.06 million in the previous period, a decline of approximately 93.5%[17] Cash Flow and Liquidity - The net cash flow from operating activities increased by 4.93% to ¥23,916,914.54, compared to ¥22,794,035.25 in the previous year[5] - Cash inflow from operating activities totaled CNY 301,796,623.37, while cash outflow was CNY 277,879,708.83, resulting in a net cash inflow[18] - Cash flow from investing activities was negative at CNY -4,540,594.19, compared to CNY -55,794,033.20 in the previous period[19] - Cash inflow from financing activities was CNY 48,000,000.00, while cash outflow was CNY 69,460,930.77, leading to a net cash outflow of CNY -21,460,930.77[19] - The ending balance of cash and cash equivalents was CNY 175,573,870.47, down from CNY 196,412,733.73 in the previous period[19] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,187,546,987.06, a slight decrease of 0.28% from ¥2,193,636,977.65 at the end of the previous year[5] - Total liabilities decreased to ¥1.03 billion from ¥1.04 billion, a decline of about 0.9%[15] - Current liabilities totaled ¥496.36 million, down from ¥524.16 million, a decrease of approximately 5.3%[15] - Long-term borrowings increased to ¥382.46 million from ¥361.67 million, an increase of about 5.2% year-over-year[15] - The company reported a significant increase in expected liabilities by 39.76% to ¥2,637,715.68 due to increased provisions for hazardous waste costs[8] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 24,629[10] - The total number of shares held by the top two shareholders, Li Xi and Chen Xinmin, is 100,865,992 shares each, accounting for 60.24% of the total share capital at the end of the reporting period[11] - The top 10 shareholders include various institutional investors, with the largest being Li Xi and Chen Xinmin, both holding 30.12% each[11] - The company has a significant pledge situation, with Li Xi pledging 80,521,385 shares, which is approximately 79.8% of his total holdings[11] - There are no significant changes in the financing and securities lending activities of the top shareholders reported[11] Operational Metrics - Total operating revenue decreased to ¥254.70 million from ¥306.09 million, a decline of approximately 16.8% year-over-year[16] - Total operating costs reduced to ¥249.33 million from ¥273.58 million, reflecting a decrease of about 8.8% year-over-year[16] - Research and development expenses increased to ¥27.50 million from ¥24.95 million, representing an increase of about 10.2% year-over-year[16] - Total current assets increased to ¥905,332,383.62 from ¥885,753,509.84, showing a growth of about 2.93%[13] - Accounts receivable decreased from ¥138,011,657.35 to ¥132,542,849.01, indicating a reduction of about 3.39%[13] - Inventory rose to ¥455,508,538.34 from ¥442,008,841.36, representing an increase of approximately 3.05%[13] Future Outlook and Reporting - The company plans to implement new accounting standards starting in 2025, which may affect financial reporting[20] - The first quarter report was not audited, indicating preliminary financial results[20] - The company has not disclosed any new product developments or technological advancements during the reporting period[12] - The company has not reported any mergers or acquisitions in the current financial period[12]

Financial Performance - The company's operating revenue for Q1 2025 was ¥116,127,263.91, a decrease of 40.08% compared to ¥193,805,595.18 in the same period last year[6] - The net profit attributable to shareholders was -¥462,709,260.27, representing a decline of 276.50% from a profit of ¥262,161,291.86 in the previous year[6] - The company reported a 40.08% decrease in operating income primarily due to reduced profits from real estate projects during the reporting period[9] - The net profit for the current period is a loss of CNY 472.15 million, compared to a profit of CNY 236.03 million in the previous period, indicating a significant downturn[21] - The total comprehensive income for the current period is a loss of CNY 472.15 million, compared to a gain of CNY 236.03 million in the previous period[21] Cash Flow and Liquidity - The net cash flow from operating activities increased by 109.51%, reaching ¥77,613,469.59, compared to -¥815,896,561.33 in the same period last year[6] - The cash flow from operating activities generated a net inflow of CNY 77.61 million, contrasting with a net outflow of CNY 815.90 million in the previous period[23] - The company received CNY 185 million in cash from borrowings during the current period, slightly up from CNY 180 million in the previous period[24] - The company reported a total cash and cash equivalents balance of CNY 651.99 million at the end of the period, up from CNY 689.41 million in the previous period[25] Assets and Liabilities - The total assets at the end of the reporting period were ¥20,991,698,345.04, a slight decrease of 0.32% from ¥21,058,044,676.67 at the end of the previous year[6] - Current assets totaled CNY 13,500,140,670.70, an increase from CNY 13,312,251,933.62 at the beginning of the period[16] - Total liabilities rose to CNY 22,040,153,866.39 from CNY 21,634,353,141.28, marking an increase of approximately 1.9%[17] - The company's total assets decreased slightly to CNY 20,991,698,345.04 from CNY 21,058,044,676.67[17] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 59,605, with the largest shareholder holding 22.43% of the shares[12] - The basic and diluted earnings per share for the current period are both CNY -0.2668, compared to CNY 0.1512 in the previous period[21] Investment and Income - Investment income fell by 124.55% compared to the previous year, mainly due to significant gains from the transfer of three subsidiaries' equity in the prior year[9] - The company incurred an investment loss of CNY 133.72 million, compared to a gain of CNY 544.76 million in the previous period[20] Operating Costs and Expenses - Total operating costs decreased to CNY 448.87 million from CNY 491.10 million, a reduction of about 8.6%[20] - Tax expenses decreased by 59.21% year-on-year, attributed to lower profits from real estate projects[9]

深圳市银宝山新科技股份有限公司 2025 年第一季度报告 证券代码：002786 证券简称：银宝山新 公告编号：2025-032 2025 年第一季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 深圳市银宝山新科技股份有限公司 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重 大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第一季度报告是否经审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减（%） | | --- | --- | --- | --- | | 营业收入（元） | 561,622,392.45 | 531,214,200.42 | 5.72% | | 归属于上市公司股东的净利润（元） | -16,252,520.42 | -28,298 ...

Financial Performance - The company's operating revenue for 2024 was ¥2,221,171,289.51, a decrease of 4.34% compared to ¥2,321,850,945.46 in 2023[19]. - The net profit attributable to shareholders for 2024 was -¥271,835,754.78, representing a decline of 211.05% from ¥244,790,653.93 in 2023[19]. - The net cash flow from operating activities for 2024 was ¥44,767,975.81, down 58.00% from ¥106,583,153.25 in 2023[19]. - The total assets at the end of 2024 were ¥3,596,638,396.05, a decrease of 12.67% from ¥4,118,498,547.38 at the end of 2023[19]. - The net assets attributable to shareholders at the end of 2024 were ¥232,205,463.44, down 52.96% from ¥493,636,920.63 at the end of 2023[19]. - The basic earnings per share for 2024 was -¥0.55, compared to ¥0.49 in 2023, reflecting a decline of 212.24%[19]. - The weighted average return on equity for 2024 was -75.42%, a decrease of 142.74% from 67.32% in 2023[19]. - The company reported a quarterly operating revenue of ¥531,214,200.42 in Q1, ¥594,833,338.92 in Q2, ¥551,907,411.76 in Q3, and ¥543,216,338.41 in Q4 for 2024[24]. - The net profit attributable to shareholders for Q4 2024 was -¥143,589,810.17, with a total of -¥56,530,271.77 in Q3, -¥43,417,483.71 in Q2, and -¥28,298,189.13 in Q1[24]. - The company experienced a significant increase in non-recurring losses, totaling -¥68,326,108.42 for 2024 compared to a gain of ¥654,387,480.51 in 2023[26]. Business Operations - The company focuses on automotive mold and parts manufacturing, aiming to enhance production capabilities and become a specialized supplier of lightweight and intelligent components[35]. - The communications and consumer electronics segment is a mature and stable core business, providing precision manufacturing solutions to major international brands such as Huawei, Cisco, and Samsung[35]. - The company has established a comprehensive mold manufacturing standard system and automated production capabilities, enhancing mold quality and reducing costs[39]. - The company has advanced capabilities in the design and production of high-end composite molds, leading in technologies such as low-pressure injection molding and multi-layer co-extrusion[40]. - The company serves leading automotive clients including BMW, Toyota, and Ford, leveraging years of technical and customer accumulation[35]. - The company is positioned in the high-end equipment sector, focusing on semiconductor equipment and IoT robotics, with clients including ASM and R&S Group[35]. - The company has a robust procurement model, ensuring timely supply based on customer orders and market research[37]. - The company employs a direct sales model, emphasizing customer relationships and service to enhance product value[38]. Research and Development - The company is committed to R&D in lightweight composite technology, providing high-performance structural components for the automotive industry[41]. - The company holds a total of 779 patents, including 85 invention patents and 495 utility model patents[45]. - The company is recognized as a national high-tech enterprise, focusing on R&D in emerging high-end consumer products and automation technologies[45]. - The number of R&D personnel decreased by 10.94% from 512 in 2023 to 456 in 2024[64]. - R&D investment amount decreased by 11.73% from ¥151,901,981.14 in 2023 to ¥134,077,916.82 in 2024[64]. - R&D investment as a percentage of operating revenue decreased from 6.54% in 2023 to 6.04% in 2024[64]. Management and Governance - The company has established a governance structure that includes a board of directors with 9 members and a supervisory board with 5 members, ensuring compliance with legal regulations[88][89]. - The company held 4 shareholder meetings and 8 board meetings during the reporting period, adhering to legal and procedural requirements[88]. - The company has a complete and independent production and operation system, with no competition with its controlling shareholders' other enterprises during the reporting period[93]. - The company has a well-defined governance structure with separate operational systems for the shareholders' meeting, board of directors, and supervisory board[92]. - The company is focused on maintaining stability during this transition period while ensuring continuity in governance[99]. Employee and Community Engagement - The company emphasizes customer satisfaction by continuously optimizing product design and service processes to meet increasing customer demands[83]. - The company has implemented measures to control production costs in response to potential increases in raw material prices[84]. - The company is committed to exploring diversified ways to participate in public welfare, focusing on education support and talent cultivation[141]. - The company provided financial assistance of 20,000 yuan to 4 employees facing major illnesses or emergencies, alleviating their economic pressure[142]. - The company helped over ten impoverished individuals achieve employment through job matching, skills training, and employment guidance during the reporting period[143]. Financial Independence and Related Party Transactions - The company maintains independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[90]. - The company has established a commitment to avoid and minimize related party transactions with Yinbao Shannxin[149]. - The company has confirmed that there are no non-operating fund occupations by controlling shareholders or related parties during the reporting period[152]. - The company has not engaged in any business that competes with Yinbao Shannxin's main operations, ensuring no conflict of interest[147]. Legal and Compliance - The company has not faced any penalties or rectification issues during the reporting period[165]. - The company has complied with all necessary approval procedures for the change of auditor[158]. - The company has not reported any significant new product developments or market expansions in the current reporting period[186]. - The company disclosed ongoing litigation and arbitration matters, with updates provided in April, August, and November 2024[195].